The Development and Evaluation of Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR)

用于药物使用障碍远程管理的增强型数字化学感应嗅觉训练的开发和评估（编辑）

• 批准号: 10741580
• 负责人: Charles Chiedu Nwaokobia
• 金额: $ 5.5万
• 依托单位: EVON MEDICS, LLC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10741580
• 关键词: Accident and Emergency department; Adoption; African American population; Agonist; Alcohol withdrawal syndrome; Beta-caryophyllene; COVID-19 pandemic; Cellular Phone; Cocaine; Cocaine use disorder; Communities; Data; Development; Disadvantaged minority; Disparity population; Evaluation; Feedback; Funding; Health Insurance Portability and Accountability Act; Hispanic Americans; Industry; Innovation Corps; Intelligence; Internet; Intervention; Intoxication; Language; Leadership; Measures; Mentorship; Methamphetamine; Methamphetamine use disorder; Patients; Pharmaceutical Preparations; Phase; Physiological; Population; Provider; Psychophysics; Pulse Rates; Remote management; Research; Running; Secure; Sensory; Small Business Innovation Research Grant; Stimulant; Substance Use Disorder; Surveys; Testing; Therapeutic; Training; Universities; Voice; Washington; Withdrawal; alcohol use disorder; cocaine use; combinatorial; craving; digital; digital treatment; effectiveness/implementation study; efficacy study; illiteracy; innovation; mHealth; marginalization; men who have sex with men; mobile computing; neighborhood disadvantage; opioid use disorder; opioid withdrawal; patient oriented; product development; programs; psychologic; randomized trial; sensor; sexual minority group; social disparities; stimulant use; stimulant use disorder; substance use; substance use treatment; treatment as usual; ward; web portal; wireless fidelity

ABSTRACT The Development and Evaluation of Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR) is a project to develop a sustainable, scalable, and patient-centered mobile health platform, comprised of (1) patient-facing culturally-adapted digital- chemosensory therapeutic for stimulant, alcohol and opioid use disorders, sensors for acquisition of objective physiological measures of substance intoxication and withdrawal, and application for running and interpreting the interventions and sensory acquisition programs; and (2) a provider-facing web portal, for substance use disorder treatment in socially-disadvantaged and sexual minority populations. Management of substance use disorders (SUD) mostly involve direct contact between patients and providers, but the precedence of COVID- 19 pandemic has elevated the need for patient-centered remote management of SUD. While digital therapeutics and mobile health platforms provide avenues for remote management, our communities of African Americans (AA), Hispanic-Americans (HA) and other socially disadvantaged populations lag in adoption of these mobile platforms, due to inability to read, digital illiteracy, lack of access to smartphones, absence of reliable Wi-Fi or internet, and financial constraints. Moreover, while interventions exist for Opioid Use Disorders (OUD), there are no drugs for cocaine or stimulant use disorders. Underserved AA and HA communities with OUD, particularly marginalized men who have sex with men (MSM), have more severe co-existing cocaine, methamphetamine, and alcohol use disorders; and digital solutions for these populations are lacking. Providers on the other hand, lack well-adapted, intelligent-based physiological and psychophysical acquisition platforms to guide remote agonist management of opioid and alcohol withdrawal. Through Phase I SBIR, EVON Medics developed a combinatorial digital chemosensory-based orbitofrontal cortex training for Opioid Use Disorder (CBOT). Based on the limitations of CBOT for our socially disadvantaged AA, HA and MSM population, we recently revised the platform for treatment of stimulant and alcohol use disorder, by including beta- caryophyllene chemosensory stimulation. We propose further product development, with innovative changes to the patient-facing platform and a new provider-facing platform to guide remote management of OUD, Stimulant (cocaine and methamphetamine) use and alcohol use disorders through Fast-Track SBIR funding. In Phase I, we will configure the patient-facing platform with: voice commands, different languages especially for the non- English speaking, non-Wi-Fi or internet-dependent connectivity solution, reliable pupillary, pulse rate and spo2 physiological acquisitions and psychological (e.g., craving) surveys; and the provider-facing component to provide interpretation of patients’ data in a HIPAA-secure portal. We will do preliminary testing in 3 substance use programs, Howard University emergency room, and community populations in the under-served Ward 8 communities in Washington, DC. In Phase II, we will perform a pilot randomized trial of EDITOR compared to treatment as usual and CBOT for office-based treatment of SUDs in several federal funded programs associated with Evon Medics and Howard University. Upon completion of Phases I and II, we will be poised to expand the research to either a larger, Phase III efficacy study, or an implementation study of effectiveness in the real-world setting through commercial partnerships developed over the course of this project. To the best of our knowledge, this will be the first evaluation of Digital-Chemosensory-Based platform for remote management of SUD, culturally adapted for socially disadvantaged communities and populations.

摘要